Sera Prognostics is a diagnostics & research business based in the US. Sera Prognostics shares (SERA) are listed on the NASDAQ and all prices are listed in US Dollars. Sera Prognostics employs 113 staff and has a trailing 12-month revenue of around $229,000.
How to buy Sera Prognostics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SERA. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Sera Prognostics stock price (NASDAQ: SERA)
Use our graph to track the performance of SERA stocks over time.Sera Prognostics shares at a glance
Latest market close | $1.52 |
---|---|
52-week range | $1.10 - $7.71 |
50-day moving average | $1.36 |
200-day moving average | $1.72 |
Wall St. target price | $3.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.84 |
Buy Sera Prognostics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sera Prognostics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sera Prognostics price performance over time
Historical closes compared with the close of $1.52 from 2023-01-31
1 week (2023-01-26) | 4.11% |
---|---|
1 month (2022-12-30) | 20.63% |
3 months (2022-11-02) | 16.92% |
6 months (2022-08-02) | -34.48% |
1 year (2022-02-02) | -78.22% |
---|---|
2 years (2021-01-29) | N/A |
3 years (2020-01-29) | N/A |
5 years (2018-01-29) | N/A |
Sera Prognostics financials
Revenue TTM | $229,000 |
---|---|
Gross profit TTM | $45,000 |
Return on assets TTM | -22.1% |
Return on equity TTM | -36.49% |
Profit margin | 0% |
Book value | $3.46 |
Market capitalisation | $45.3 million |
TTM: trailing 12 months
Sera Prognostics share dividends
We're not expecting Sera Prognostics to pay a dividend over the next 12 months.
You may also wish to consider:
- Quest Diagnostics Incorporated (DGX.US) (1.81% forward annual dividend yield)
- Johnson-and-Johnson (JNJ.US) (2.69% forward annual dividend yield)
Sera Prognostics overview
Sera Prognostics, Inc. , a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. .
Frequently asked questions
What percentage of Sera Prognostics is owned by insiders or institutions?Currently 14.857% of Sera Prognostics shares are held by insiders and 47.44% by institutions. How many people work for Sera Prognostics?
Latest data suggests 113 work at Sera Prognostics. When does the fiscal year end for Sera Prognostics?
Sera Prognostics's fiscal year ends in December. Where is Sera Prognostics based?
Sera Prognostics's address is: 2749 East Parleys Way, Salt Lake City, UT, United States, 84109 What is Sera Prognostics's ISIN number?
Sera Prognostics's international securities identification number is: US81749D1072
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert